Tigecycline: A Critical Update

References

• Amyes SG. Enterococci and streptococci. Int J Antimicrob Agents. 2007; 29 (3): S43–52.
   PubMedGoogle Scholar
• Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol 2007; 8 (5): 259–70.
   PubMed Web of Science ®Google Scholar
• Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-ab-dominal infections: evidence for pooled clinical studies compar-ing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt). 2007; 8 (2): 159–72.
   PubMedGoogle Scholar
• Cerda E, Abella A, de la Cal Miguel A. Enteral vancomycin controls methicillin-resistant Staphylococcus aureus endemicity in an intensive care burn unit: a 9-year prospective study. Ann Surg 2007; 245 (3): 397–407.
   PubMed Web of Science ®Google Scholar
• Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother. 2007; 41 (6): 965–72.
   PubMed Web of Science ®Google Scholar
• Goff DA, Dowzicky MJ. Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcy-cline antimicrobial. J Med Microbiol 2007; 56(Pt 9): 1189–93.
   PubMed Web of Science ®Google Scholar
• Tuckman M, Petersen PJ Howe AY. Occurrence of tetra-cycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother 2007; 51 (9): 3205-11.
   PubMed Web of Science ®Google Scholar
• Sotto A, Bouziges N, Jourdan N, Richard JL, Lavigne JP. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris). 2007. Pubmed(in process).
   Google Scholar
• Tygacilm (tigecycline) package label. Wyeth Pharmaceuti-cals, Inc., PA, USA.
   Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56 (3): 470–480.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Homenuik K, Nichol K et al. The glycylcy-clines: A comparative review with the tetracyclines. Drugs 2004; 64 (1): 63–88.
   Google Scholar
• Rubinstein E, Vaughan D. Tigecycline: A novel glycylcy-line. Drugs 2005; 65 (10): 1317–1336.
   PubMed Web of Science ®Google Scholar
• Garrison MW, Neumiller JJ, Setter SM. Tigecycline: An investigational glycylcycline antimicrobial with activity against re-sistant gram-positive organisms. Clin Ther 2005; 27 (1): 12–22.
   PubMed Web of Science ®Google Scholar
• Ruit AC, Florijn A, Verhoef J, Milatovic D. 2005. Pres-ence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636–1638.
   Google Scholar
• Olson MW, Ruzin A, Feyfant E, Rush III TS, O'Connell J, Bradford PA. Functional, biophysical, and structural bases for an-tibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006; 50 (6): 2156–2166.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51 (6): 2065–2069.
   PubMed Web of Science ®Google Scholar
• Draghi, DC, Tench, SL, Jones, ME, et al. Longitudinal analysis of tigecycline (TIG) activity against geographically diverse Staphylococcus aureus (SA), Acinetobacter spp. (AB), and En-terobacteriaceae (EN) exhibiting multi-drug resistant (MDR) phe-notypes (abstract). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. American Society of Microbiology, E-0744.
   Google Scholar
• Meagher AK, Passarell JA, Cirincione BB. Exposure-re-sponse analyses of tigecycline efficacy in patients with compli-cated skin and skin-structure infections. Antimicrob Agents Chemother. 2007; 51 (6): 1939–1945.
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Jiang Y. Comparative activities of dap-tomycin, linezolid, and tigecycline against catheter-related me-thicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007; 51 (5): 1656–1660.
   PubMed Web of Science ®Google Scholar
• lzdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob Agents Chemother 2007; 51 (4): 1155–1163.
   PubMed Web of Science ®Google Scholar
• Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial sus-ceptibility among pathogens collected from hospitalized patients in the united states and in vitro activity of tigecycline, a new gly-cylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50 (10): 3479–3484.
   PubMed Web of Science ®Google Scholar
• Package insert. Tygacil (tigecycline) for injection. Philadel-phia, PA: Wyeth Pharmaceuticals, June 2005.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49 (1): 220–229.
   PubMed Web of Science ®Google Scholar
• Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 (1): 12–22.
   PubMedGoogle Scholar
• Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effect of age and sex in single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49 (4): 1656–1659.
   PubMed Web of Science ®Google Scholar
• Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, random-ized, open-label efficacy and safety study of two doses of tigecy-cline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26 (5): 704–714.
   Google Scholar
• Sun HK, Ong CT, Umer A et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49 (4): 1629–1632.
   Google Scholar
• Rodvold K.A., Gotfried M.H., Cwik M., et al. Serum, tis-sue, and body fluid concentrations of tigecycline after a single 100-mg dose. J Antimicrob Chemother 2006; 58 (6): 1221–1229.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kelly MG Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharma-codynamics of tigecycline. Int J Antimicrob Agents 2005; 25 (6): 523–529.
   Google Scholar
• Agwuh KN, MacGowan A. Pharmacokinetics and phar-macodynamics of the tetracyclines including glycylcyclines. J An-timicrob Chemother 2006; 58 (2): 256–265.
   PubMed Web of Science ®Google Scholar
• Van Ogtrop ML, Andes D, Stamstad TJ et al. In vivo phar-macodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44 (4): 943-949.
   Google Scholar
• Stein GE, Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43 (4): 518–524.
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus au reus disease in three communities. N Engl J Med 2005; 352 (14): 1436-1444.
   Google Scholar
• Postier RG, Green SL, Klein SR et al. Results of a multi-center, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure in-fections in hospitalized patients. Clin Ther 2004; 26 (5): 704–714.
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treat-ment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (5): S341-S353.
   Google Scholar
• Murray J, Wilson S, Klein Setal. The clinical response to tigecycline in the treatment of complicated intra-abdominal in-fections in hospitalized patients, a Phase 2 clinical trial. Pro-ceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, L-739.
   Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of com-plicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 (5): S354–S367.
   PubMedGoogle Scholar
• Mallick R, Sun S, Schell SR. Predictors of efficacy and health resource utilization in treatment of complicated intra-ab-dominal infections: evidence for pooled clinical studies compar-ing tigecycline with imipenem-cilastatin. Surg Infect (Larchmt). 2007; 8 (2): 159–72.
   PubMedGoogle Scholar
• Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DG, Fruncillo RJ. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. Pro-ceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC.
   Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49 (1): 220–229.
   PubMed Web of Science ®Google Scholar
• Lefort A, Lafaurie M, Massias L et al. Activity and diffu-sion of tigecycline(GAR-936) in experimental enterococcal en-docarditis. Antimicrob Agents Chemother 2003; 47 (1): 216-222.
   Google Scholar
• Montvale NJ, Drug topicsred book.: Thomson Health-care, 2006.
   Google Scholar
• Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Microbiol Antimi-crob 2007; 6: 4.
   PubMedGoogle Scholar
• Khan AU, Musharraf A. Plasmid-mediated multiple an- tibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection. Med Sci Monit 2004; 10 (11): CR598-602.
   Google Scholar
• Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria- a description of the action, resistance mecha-nism, and nosocomial battleground. J Biomed Sci DOI 10.1007/s11373-007-9194-y.
   Google Scholar
• Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy. 2007; 27 (8): 1198–201.
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. 2007; 59 (4): 772–4.
   Web of Science ®Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter bau-mannii. Pharmacotherapy. 2007; 27 (7): 980–7.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R et al. Acinetobacter baum-abnnii bloodstream infection while receiving tigecycline: a cau- tionary report. J Antimicrob Chemother. 2007; 59 (1): 128–31
   Google Scholar
• Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 2007: 13 (10): 949–952.
   PubMed Web of Science ®Google Scholar
• SOUll M, Kontopidou FV, Koratzanis E et al. In vitro ac-tivity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek Hospitals. Antimicrob Agents Chemother. 2006; 50 (9): 3166–3169.
   Google Scholar
• Edelstein PH, Weiss WJ, Edelstein MAC. Activities of tige-cycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2003; 47 (2): 533-540.
   Google Scholar
• Dizbay M, Kilic S, Hizel K, Arman D. Tigecycline: its po-tential for treatment of brucellosis. Scand J Infect Dis. 2007; 39 (5): 432–4.
   PubMed Web of Science ®Google Scholar
• Moore IF, Hughes DW, Wright GD. Tigecycline is modi-fied by the flavin-dependent monooxygenase TetX. Biochemistry. 2005; 44 (35): 11829–35.
   PubMed Web of Science ®Google Scholar